Defying expectations, BioNTech and Moderna each designed and developed highly effective coronavirus shots far faster than previously considered possible. Read more ➔

A billion-dollar deal with Merck followed quick approvals for the company's second and third drugs, pushing Seagen's market value to over $30 billion. Read more ➔

The U.K.'s RECOVERY trial proved a cheap steroid could keep COVID-19 patients from dying, and showed two other widely considered drugs didn't work — crucial findings in a sprawling, global hunt for coronavirus treatments. Read more ➔